Table 3. Trends in antimicrobial resistance rates of Enterobacteriaceae during the study period (n = 998).
| Antibiotics | Susceptibility rates, n (%) | P-value | ||||
|---|---|---|---|---|---|---|
| 2012 (n = 181) | 2013 (n = 216) | 2014 (n = 184) | 2015 (n = 216) | 2016 (n = 201) | ||
| AMP | 122 (67.4) | 144 (66.7) | 119 (64.7) | 132 (61.1) | 128 (63.7) | 0.222 |
| AMC | 32 (17.7) | 44 (23.9) | 51 (23.6) | 40 (19.9) | 0.298 | |
| TZP | 5 (4.1) | 6 (2.8) | 6 (3.3) | 6 (2.8) | 10 (5.0) | <0.001 |
| FOX | 16 (8.8) | 22 (10.2) | 30 (16.3) | 19 (8.8) | 15 (7.5) | 0.498 |
| CTX | 19 (10.5) | 27 (12.5) | 31 (16.8) | 27 (12.5) | 31 (15.4) | 0.220 |
| CAZ | 3 (1.7) | 6 (2.8) | 6 (7.1) | 7 (3.2) | 10 (5.0) | 0.117 |
| FEM | 0 (0) | 4 (1.9) | 7 (3.8) | 6 (2.8) | 7 (3.5) | 0.027 |
| ATM | 8 (4.4) | 11 (5.1) | 16 (8.7) | 11 (5.1) | 14 (7.0) | 0.362 |
| EPM | 0 (0) | 0 (0) | 2 (1.1) | 0 (0) | 0 (0) | <0.001 |
| IPM | 0 (0) | 0 (0) | 3 (1.6) | 0 (0) | 0 (0) | <0.001 |
| FQa | 43 (23.8) | 48 (22.2) | 52 (28.3) | 46 (21.3) | 43 (21.4) | 0.546 |
| GEN | 40 (22.1) | 42 (19.4) | 49 (26.6) | 32 (14.8) | 38 (18.9) | 0.214 |
| AMK | 0 (0) | 1 (0.5) | 0 (0) | 0 (0) | 0 (0) | 0.458 |
| TMP/SMX | 58 (32.0) | 74 (34.3) | 60 (32.6) | 62 (28.7) | 62 (30.8) | 0.419 |
aCiprofloxacin and/or levofloxacin
AMP, ampicillin; AMC, amoxicillin-clavulanic acid; TZP, piperacillin-tazobactam; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; EPM, ertapenem; IPM, imipenem; FQ, fluoroquinolones; GEN, gentamicin; AMK, amikacin; TMP/SMX, trimethoprime-sulfamethoxazole